Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Exenatide Once Weekly in T2DM with TZD
NCT00753896Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2008
- Primary completion
- Jul 2009
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Primary endpoints: Percentage of Patients Experiencing Adverse Events at 52 weeks and Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events at 52 weeks. Started Oct 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00753896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00753896.